Digest Network How does it work
Network
/
Society
Al
Not verified

Alnylam Pharmaceuticals, Inc.

What we write about

BiotechnologyHealthMedicine - variousPharmaceuticalsWEB AND SOCIAL NETWORK

37 Press releases

View all press releases
09/06/2025
Scienza
Cardiology
Biotechnology
Pharmaceuticals
Health
Medicine - various
Labour market
Industria
Alnylam Receives European Commission Approval for AMVUTTRA® (vutrisiran) for the Treatment of ATTR Amyloidosis with Cardiomyopathy
Source
Alnylam Pharmaceuticals, Inc.
Issuer
Business Wire
1.00
0
28/05/2025
Biotechnology
Pharmaceuticals
Health
Sanità
Eventi
WEB AND SOCIAL NETWORK
Alnylam to Webcast Presentation at Goldman Sachs 46th Annual Global Healthcare Conference
Source
Alnylam Pharmaceuticals, Inc.
Issuer
Business Wire
1.00
0
20/05/2025
Responsabilità sociale d'impresa
Industria
Health
Medicine - various
Scienza
Pharmaceuticals
Biotechnology
Alnylam Issues 2024 Corporate Responsibility Report
Source
Alnylam Pharmaceuticals, Inc.
Issuer
Business Wire
1.00
0
17/05/2025
Eventi
Industria
Health
Medicine - various
Scienza
Pharmaceuticals
Cardiology
Biotechnology
AMVUTTRA® (vutrisiran) Significantly Reduces Mortality and a Range of Important Cardiovascular Events in Patients with ATTR Amyloidosis with Cardiomyopathy: Additional Data from HELIOS-B
Source
Alnylam Pharmaceuticals, Inc.
Issuer
Business Wire
1.00
0
12/05/2025
Eventi
Industria
Scienza
Biotechnology
Medicine - various
Cardiology
Sanità
Pharmaceuticals
Health
Alnylam to Share Progress Across its Transthyretin Amyloidosis Franchise Including Additional Analyses of the HELIOS-B Phase 3 Study Results at Heart Failure 2025 Congress
Source
Alnylam Pharmaceuticals, Inc.
Issuer
Business Wire
1.00
0
05/05/2025
Eventi
WEB AND SOCIAL NETWORK
Biotechnology
Pharmaceuticals
Health
Alnylam to Webcast Presentation at BofA Securities 2025 Health Care Conference
Source
Alnylam Pharmaceuticals, Inc.
Issuer
Business Wire
1.00
0
01/05/2025
WEB AND SOCIAL NETWORK
Phones and Miscellaneous
stock market
Biotechnology
Food hygiene
Health
Pharmaceuticals
Alnylam Pharmaceuticals Reports First Quarter 2025 Financial Results and Highlights Recent Period Progress
Source
Alnylam Pharmaceuticals, Inc.
Issuer
Business Wire
1.00
0
28/04/2025
Industria
Cardiology
Biotechnology
Food hygiene
Health
Sanità
Pharmaceuticals
Scienza
Medicine - various
Alnylam Receives Positive CHMP Opinion for Vutrisiran for the Treatment of ATTR Amyloidosis with Cardiomyopathy
Source
Alnylam Pharmaceuticals, Inc.
Issuer
Business Wire
1.00
0
17/04/2025
WEB AND SOCIAL NETWORK
Phones and Miscellaneous
Finance
stock market
Biotechnology
Pharmaceuticals
Health
Sanità
Alnylam to Webcast Conference Call Discussing First Quarter 2025 Financial Results
Source
Alnylam Pharmaceuticals, Inc.
Issuer
Business Wire
1.00
0
01/04/2025
Eventi
WEB AND SOCIAL NETWORK
Biotechnology
Pharmaceuticals
Health
Alnylam to Webcast Presentation at Needham 24th Annual Virtual Healthcare Conference
Source
Alnylam Pharmaceuticals, Inc.
Issuer
Business Wire
1.00
0

Contact details

Social Media

Followers
0
Compatibility
0